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Abstract
Background—Brain metastases (BM) arising from Triple-negative breast cancer (TNBC) 
portend poor prognosis. TNBC is more common in premenopausal and African-American (AA) 
patients; both also confer poor prognosis. In a single institution cohort study, we sought to 
determine if inferior outcome of TN BCBM is more reflective of a higher-risk population or 
subtype itself.
Methods—The UNC Breast Cancer Database identified pts with BCBM diagnosed 1988 – 2008. 
BC subtype was assigned by IHC: HR+ (hormone receptor, ER+ and/or PR+)/HER2−, HR+/
HER2+, HR−/HER2+ and TN (ER−/PR−/HER2−). Survival and recurrence patterns were 
evaluated by subtype, age (< vs ≥ 40 years) and race (AA vs non-AA) using the Kaplan-Meier 
method and Cox regression.
Results—Among 119 patients with BCBM, 33% were AA and 31% aged < 40 yrs. BC subtype 
was confirmed in 98 patients: 30% HR+/HER2−, 21% HR+/HER2+, 18% HR−/HER2+, 31% TN. 
Survival after BM was impacted by subtype (p=0.002), shortest for TNBC (0.24 yrs, CI 0.17 – 
0.48). There were no age- (p=0.84) or race-specific (p=0.09) differences in survival after BM; 
stratification of subtypes by age and race revealed no difference (all, p > 0.1). Receipt of systemic 
therapy after BCBM was an important predictor of survival following BCBM (HR = 0.29, 
p=0.002) when adjusted for race, age, number of CNS lesions and BC subtype.
Conclusions—TNBC confers a high risk of death following BM regardless of race and age 
supporting the need for novel agents capable of controlling both intra- and extracranial TNBC 
across all races and ages.
INTRODUCTION
Brain metastases are a burgeoning clinical problem which negatively impact approximately 
30% of patients diagnosed with advanced breast cancer1, 2. Despite local and systemic 
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therapeutics, prognosis following a diagnosis of brain metastases arising from breast cancer 
is quite poor; historically, one year survival is approximately 20% across all breast cancer 
subtypes3. Breast cancer is no longer viewed as a homogenous disease process, but rather a 
compilation of reproducibly-identified intrinsic subtypes as defined by microarray -- 
Luminal A, Luminal B, Basal-like and HER2-enriched subtypes – each characterized by 
unique clinico-pathologic features and distinct prognosis4–6. Moreover, gene expression 
studies have identified subtype-specific predilection to distant metastatic sites7. Endocrine-
sensitive tumors are more likely to recur in bone, while Basal-like and HER2-positive breast 
tumors in visceral sites, including the central nervous system (CNS) -- a site historically 
difficult to treat due to properties inherent to the blood brain barrier 8.
Building on these observations, several groups have sought to determine the contribution of 
intrinsic breast cancer subtype to the incidence, behavior, and prognosis of CNS metastases. 
Studies largely from eastern European and Asian patient populations suggest a high 
incidence and aggressive nature of brain metastases arising from Basal-like (usually 
identified as “Triple-negative” on clinical assays for HER2 and the estrogen [ER] and 
progesterone [PR] receptors) breast tumors9–12.
Basal-like/triple-negative breast cancer is a subtype of breast cancer commonly diagnosed in 
premenopausal and African American women – clinical factors which have both been 
correlated with poorer breast cancer outcome13–15. It is not clear whether or not the inferior 
outcome of Basal-like/triple-negative breast cancer brain metastases is a reflection of a 
higher-risk baseline population or of subtype itself. To our knowledge, the prognostic 
interplay of breast cancer subtype, race and age has yet to be explored in a cohort of 
racially-diverse patients diagnosed and treated for breast cancer and brain metastases.
In this single institution cohort study, we examined the clinico-pathologic characteristics and 
outcome of breast cancer patients diagnosed with brain metastases who received treatment at 
the University of North Carolina (UNC) at Chapel Hill between the years of 1988 – 2008. 
The goals of this study were: (1) to evaluate the clinical and pathologic characteristics of 
both primary breast and metastatic CNS tumors, (2) to report practice patterns (including 
both local and systemic therapies) among patients diagnosed with breast cancer-related brain 
metastases, and (3) to determine the contribution and interaction of breast cancer subtype, 
race and age on outcomes, particularly after CNS recurrence.
MATERIALS AND METHODS
Patient Population
This retrospective study was approved by the UNC Chapel Hill Office of Human Research 
Ethics Committee Institutional Review Board. Using an electronic clinical breast cancer 
database maintained at UNC Chapel Hill which includes >1,400 patients diagnosed with 
breast cancer between 1988 and 2008 who received a cancer-related treatment at UNC 
Hospitals, 119 patients (of which 25 patients were treated at UNC exclusively for brain 
metastases) were diagnosed with CNS metastases and were selected for study. A waiver of 
consent was granted by the UNC IRB to conduct this study given that all clinical data 
remained de-identified to study investigators.
Anders et al. Page 2






















The UNC clinical breast cancer database routinely includes clinical, treatment and outcome 
data from clinical and translational trial participants and patients treated with preoperative 
systemic therapy. Disease and vital status are updated yearly. Annual patient follow-up 
included a chart review of radiology reports, clinical notes, pathology reports and vital status 
(via the medical record, Social Security Death Index and obituaries).
Primary breast tumor characteristics
All 119 patients had a histologic confirmation of invasive breast cancer (with the exception 
of 2 initially diagnosed with ductal carcinoma in situ) and an eventual diagnosis of CNS 
metastases. The majority (77%, 92/119) of primary breast tumor pathologic specimens were 
reviewed by breast pathologists at UNC Chapel Hill. The remaining 23% (27/119) received 
their initial therapy at outside institutions and, therefore, did not have pathologic specimens 
reviewed by UNC breast pathologists. In these cases, pathology data was extracted from the 
medical record. Clinical variables included patient age, gender, race, stage of primary breast 
cancer at diagnosis, primary tumor size, lymph node stage at diagnosis, primary tumor 
histology including estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 
status, presence or absence of lymphovascular invasion (LVI) within the primary breast 
tumor, and treatment history (including local and systemic therapies).
Initial breast cancer staging was coded according to the 2003 Sixth Edition of the American 
Joint Committee on Cancer (AJCC). Primary tumor histological type (i.e. ductal or lobular) 
and grading of primary breast tumors were classified according to the Nottingham 
modification of the Scarff-Bloom-Richardson criteria. ER and PR status reported via the 
clinical database was performed by ligand binding assay (up to 1993) or 
immunohistochemistry (IHC, 1993-present). HER-2 status reported via the clinical database 
was determined either by IHC or fluorescence in situ hybridization (FISH). HER2 was 
reported as negative if either 0 or 1+ by IHC or FISH non-amplified. HER2 was reported as 
positive if 3+ by IHC or FISH amplified. In the rare case where HER2 was 2+ by IHC and 
FISH data was unavailable, samples were reported as HER2 negative (n = 7).
Central nervous system metastases-specific data
All patients included in the analysis were diagnosed with breast cancer metastatic to the 
CNS. CNS metastases were defined by the presence of metastatic disease to the brain 
parenchyma and/or the presence of leptomeningeal disease (LMD). CNS-specific data 
extracted from the database included number of CNS metastases, local CNS-specific 
therapies including neurosurgical resection, whole brain radiotherapy and focused brain 
radiotherapy. Presence or absence of extracranial disease was also recorded. Details on 
systemic therapies in the metastatic setting were extracted from the database.
Immunohistochemical Assays for ER, PR and HER2
Archival formalin-fixed, paraffin-embedded tumor tissues were available for 35 of the 119 
patients and ER, PR and HER2 status were repeated via IHC for this subset of patients. 
Among these 35 patients, both primary breast tumor tissue and brain metastases tissue were 
available in the UNC Surgical Pathology Archives or Tissue Procurement Facility for 14 
(matched pairs), brain metastases tissue only for 18, and primary breast tumor tissue only for 
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3. Approval to study clinically-annotated, de-identified tissues was obtained from the UNC 
Institutional Review Board.
IHC studies were performed on 5-micron formalin-fixed paraffin-embedded (FFPE) tissue 
sections on coated glass slides. A sequential immunohistochemical assay was performed on 
the Dako Autostainer platform (DakoCytomation). Respective monoclonal antibodies were 
applied for 30–60 minutes (with the exception of HER2 which was incubated overnight at 
4C). Detection was completed by incubating with a biotinylated link. An avidin biotin 
complex (Vectastain Elite Kit 6102) was applied followed by diaminobenzidine (Innovex 
NB314SB) chromogen for nuclear localized antibodies (ER and PR); Vector SG Substrate 
SK-4700 for the membrane localized antibodies (HER2). Signal contrast was maximized by 
counterstaining in hematoxylin (DakoCytomation Mayer’s Hematoxylin S3309), rinsed in 
deionized water and placed in a bluing solution (Richard-Allan Scientific 7301) for the 
nuclear antibodies (ER and PR) and Vector Nuclear Fast Red H3403 for HER2. The 
following primary antibodies and dilutions were employed: Estrogen receptor (clone 1D5 
1:50, Dako), Progesterone receptor (clone 16, 1:70, Vision BioSystems), and HER2 (clone 
CB11, 1:100, BioGenex). For each antibody, primary breast tumor tissue was used as a 
positive control.
Estrogen and progesterone receptor staining were scored using the Allred scoring system on 
a scale from 0–8 for nuclear staining only. The intensity score and percentage score are 
added to obtain the Allred score. Allred scores of 0–2 were classified as negative and Allred 
scores of 3–8 were classified as positive. HER2 was scored using the current ASCO/CAP 
guidelines16. Membranous immunoreactivity was scored (0 and 1+=negative, 
2+=indeterminate, 3+=positive for overexpression) and percentage of tumor cells staining 
positive were given as raw score ranging from 0–100%. For the purposes of this analysis, 0 
– 2+ was considered HER2 negative; 3+, HER2 positive.
Assignment of Breast Cancer Subtype
Clinical breast cancer subtype was assigned by IHC as previously described: HR+ (hormone 
receptor ER+ and/or PR+)/HER2−, HR+/HER2+, HR−/HER2+, and Triple-negative (ER
−/PR−/HER2−)13. In the cases where primary breast ER, PR and HER2 status were known 
via both the clinical database and repeat IHC, repeat receptor status via IHC was prioritized 
over information from the database to assign subtype. If receptor status was unknown for 
primary breast specimens (via repeat IHC or from the clinical database), available ER, PR 
and HER2 from brain specimens was used to assign subtype, again prioritizing repeat IHC 
over information from the clinical database. Concordance between clinical database 
assignment of ER, PR and HER2 and that of repeat IHC among breast tumor samples where 
both were known was 91% (10/11), 73% (8/11), and 79% (11/14), respectively. 
Concordance between clinical database assignment of ER, PR and HER2 and repeat IHC 
among brain metastases samples where both were known was 88% (7/8), 44% (4/9), and 
100% (12/12), respectively.
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The Kaplan-Meier method and Log-rank test were used to compare differences among 
survival curves, and Cox regression was used to evaluate possible predictors in the time-to-
event outcomes. Overall survival (OS) was available for all patients included in this 
retrospective review, and was defined as the time from primary breast tumor diagnosis to 
death or last contact. Time to CNS recurrence (TTCNS) was defined as the time from 
primary breast tumor diagnosis to date of CNS metastasis; for those patients whose initial 
distant recurrence included CNS, this time is the same as time to distant recurrence. CNS-
specific survival (CNS survival) was defined as the time from the date of CNS metastasis to 
the date of death or last contact. Due to missing data, the sample size available for 
multivariable modeling was limited, such that all variables (from univariable analysis) were 
not included in a single model. Thus, four multivariable models were constructed. The first 
included Triple-negative status with age, race, and > 3 brain metastases. The remaining three 
models included those four variables with the addition of one of the treatments after brain 
metastases: systemic therapy, neurosurgical resection, or radiation. Statistical analyses were 
performed with SAS 9.2 statistical software (SAS Institute Inc, Cary, NC).
RESULTS
Characteristics of Study Population
The clinical characteristics of the study population are presented in Table 1. The median age 
at breast cancer diagnosis was 44 years (range 23–83 years); 31% were aged less than 40 
years. The majority of patients were female (118/119, 99%). Fifty-eight percent (62/106) 
were pre-menopausal at diagnosis, while 42% (44/106) were post-menopausal. Among the 
study population, 62% were Caucasian and 33% were African American.
Clinical and pathological characteristics of primary breast carcinomas
The majority of patients (47%) presented with stage III disease; 28% with stage IV disease. 
Median tumor size was 3 cm (range 0 – 14 cm, 83 assessable patients) and 90% (78/87) of 
patients had primary breast tumors ≥ 2 cm. Seventy-three percent (65/89) of patients with 
known lymph node status had positive axillary lymph nodes at diagnosis. Thirty-five percent 
(30/85) of breast tumors exhibited lymphovascular invasion (LVI). There were no 
significant differences in primary breast cancer characteristics, including stage at diagnosis, 
tumor size, lymph node status, presence/absence of LVI, or grade by race (AA versus non-
AA, all p > 0.05), age (< 40 versus ≥ 40 years, all p > 0.05) or subtype (all > 0.05).
Fifty-eight percent of (61/106) of primary breast tumors were ER negative and 65% 
(66/102) were PR negative, while 40% (38/94) were HER2 positive; no significant age- or 
race-specific differences in primary breast tumor ER, PR and HER2 status were seen. All 
clinical breast cancer subtypes were represented: 30% HR+/HER2−, 21% HR+/HER2+, 
31% Triple-negative, and 18% HR−/HER2+, see Table 1. Consistent with prior reports13, a 
higher proportion of younger, AA patients were diagnosed with Triple-negative (versus non-
Triple negative) breast cancer when compared to older, non-AA patients (64% [9/14] versus 
29% [14/48], p = 0.03).
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Local and systemic therapies for primary breast cancer diagnosis
As patients included in this analysis were treated either on a clinical trial or with 
preoperative systemic therapy, the large majority (89%, 104/117) received chemotherapy 
with curative intent. Half of patients treated with chemotherapy received both an 
anthracycline and taxane (50%, 50/101). Nineteen percent (22/115) received trastuzumab 
(Herceptin, Genentech/Roche) in the neoadjuvant or adjuvant setting, of which 45% had HR
+/HER2+, 45% HR−/HER2+ breast tumors. One patient with HR+/HER2− and one with 
Triple-negative breast cancer also received trastuzumab. Forty-four percent (50/113) of 
patients received endocrine therapy. There were no significant race or age-specific 
differences in primary breast cancer systemic therapies with one exception -- a higher 
proportion of AA patients received chemotherapy in the neo-adjuvant setting (70% [21/30] 
versus 44% [25/57] non-AA, p = 0.04). As expected, a higher proportion of patients with 
HR+ (both HER2− and +) breast tumors received endocrine therapy (p < 0.001), while a 
higher proportion with HER2+ (both HR- and +) breast tumors received trastuzumab (p < 
0.001).
Characteristics and treatment of CNS and non-CNS metastatic disease
Among the 119 breast cancer patients with CNS metastases, 88% (105/119) of CNS lesions 
were parenchymal, 9% leptomeningeal, and 3% both, see Table 2. At the time of metastatic 
presentation, 59% were diagnosed with extracranial disease only, 27% with intracranial 
disease only, and 14%, both. Forty-three percent of patients presented with a solitary brain 
metastasis while 38% presented with > 3 CNS metastatic lesions. There were no age-, race-, 
or subtype specific differences in number of CNS lesions or site of initial recurrence (all p > 
0.05).
Among the 118 patients for which CNS local therapy information was available, 42% 
received whole brain radiation (WBRT), 10% surgical resection, 8% radiosurgery, 13% 
surgical resection and WBRT, 7% radiosurgery and WBRT, and 20% other. Numerically, a 
higher proportion of patients with HR+/HER2+ breast cancer underwent neurosurgical 
resection, see Table 3. There were no age, race or subtype-specific differences in receipt of 
intracranial radiation (all p > 0.05).
In the metastatic setting, 75% (80/107) of patients received chemotherapy, of which 95% 
(76/80) received more than one line of chemotherapy (median of 3 lines). Although no age-
related differences were seen, a lower proportion of AA patients received > 3 lines of 
chemotherapy at any time during the metastatic disease course (19% [7/36] versus 47% 
[33/70] for non-AA patients, p = 0.02). Thirty-four percent (34/99) of patients received 
trastuzumab in the metastatic setting, while 38% (38/99) received endocrine therapy.
Focusing specifically on treatment following CNS recurrence, 61% (60/99) received 
systemic therapy after CNS recurrence among which subtype-specific differences were not 
present (p = 0.07, see Table 3). As expected, a higher proportion of patients with HER2+ 
(both HR− and +) received trastuzumab (p = 0.0005), while a higher proportion of patients 
with HR + (both HER2 − and +) received endocrine therapy (p = 0.04). Although a 
numerically higher proportion of patients with TNBC presented with both intra- and 
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extracranial disease (see Table 2), a lower proportion of patients with TNBC received 
chemotherapy after brain metastases compared to other subtypes (p = 0.03). There were no 
race- or age-related differences in treatment after CNS recurrence (all p > 0.14).
Overall Survival and Natural History of CNS Recurrence
At a median follow-up of 6.2 years, 93 of 119 (78%) of patients had died. Across all ages, 
races and breast cancer subtypes, median overall survival (OS) was 4.03 years (95% CI, 
3.09–5.05 years). Median OS differed significantly by subtype (p=0.017). Patients with 
Triple-negative breast cancer had shorter median OS, 2.12 years (CI, 1.14–3.45 years), when 
compared with other subtypes; HR−/HER2+ 3.52 years (CI, 1.61–7.5 years), HR+/HER2− 
5.09 years (CI, 3.22–7.24 years), and HR+/HER2+ 5.19 years (CI, 2.1–10.05). Although 
there was no difference in OS by age (< or ≥ 40 years, p = 0.51), AA patients experienced 
shorter median OS when compared to non-AA patients (3.45 [CI, 1.92 – 4.98] versus 4.78 
[CI, 3.52 – 6.04] years, respectively; p = 0.04).
The median time to the development of CNS metastases (TTCNS) across subtype, race and 
age was 2.62 years (CI, 1.85–3.23 years). TTCNS approached a significant association by 
breast cancer subtype (p = 0.08). TTCNS was shorter for patients with Triple-negative and 
HR−/HER2+ breast tumors (1.51 [CI, 1.08–2.31] and 1.65 [CI, 1.13 – 3.02] years, 
respectively). In contrast, TTCNS was 3.35 (CI, 1.75 – 4.98) years for HR+/HER2− and 
4.15 (CI, 0.85 – 4.54) years for HR+/HER2+ subtypes. Although TTCNS recurrence did not 
differ by age (p = 0.43), TTCNS was shorter for AA patients when compared to non-AA 
patients (2.08 [CI, 1.30 – 3.21] versus 3.06 [CI, 1.85 – 3.82] years, respectively; p = 0.02).
CNS-specific Survival by Subtype, Race and Age
Across subtype, race and age, the median time to death following CNS metastases (CNS 
survival) was 0.65 years (0.48 – 0.98). CNS survival differed significantly by subtype 
(p=0.002, see Figure 1). CNS survival was 0.24 years (CI, 0.17 – 0.48), 1.19 years (CI, 0.27 
– 3.02), 0.8 years (CI, 0.35 – 1.54), and 1.27 years (CI, 0.65 – 3.37) for Triple-negative, HR
−/HER2+, HR+/HER2− and HR+/HER2+ subtypes, respectively. There was no difference 
in CNS survival by race (p = 0.09) or age (p = 0.84). Moreover, stratification by breast 
cancer subtype revealed no difference in CNS survival by race and age (all, p > 0.1).
Impact of Subtype, Age, Race and Treatment on CNS-specific Survival
The triple-negative phenotype, presence of > 3 brain lesions, lack of neurosurgical resection, 
non-receipt of systemic or radiotherapy following CNS recurrence, and node positive status 
at primary breast cancer diagnosis predicted worse survival after brain metastases in 
univariable analysis, see Table 4. Triple-negative breast cancer (controlled for age, race, and 
> 3 brain metastases) was associated with worse survival following CNS recurrence (HR: 
2.3 [95% CI: 1.33, 3.96], p=0.003) when compared to non-Triple-negative breast cancer in 
multivariable analysis.
Taking into account the significant univariable association between treatment for brain 
metastases and improved CNS-specific survival, multivariable modeling revealed the 
following. After controlling for age, race, and >3 brain metastases, receipt of any systemic 
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treatment after brain metastases was the most important predictor of CNS-specific survival 
(HR = 0.4, p=0.002), above that of Triple-negative status (HR = 1.4, p = 0.3). However, 
Triple-negative status retained its significant association with CNS-specific survival after 
controlling for age, race, >3 brain lesions and resection (Triple-negative (HR = 2.8, 
p=0.0005), neurosurgical resection (HR = 0.4, p=0.005)) and radiation (Triple-negative (HR 
= 2.1, p=0.0009), radiation (HR = 0.5, p=0.028)).
DISCUSSION
Results from this single-institution, retrospective cohort study illustrate that Triple-negative 
breast cancer portends worse survival following a diagnosis of CNS metastases when 
compared to non-Triple-negative subtypes independently of AA race or young age. 
Moreover, within an inherently young, racially-diverse patient population treated in the 
United States, of which 33% were AA and 31% aged less than 40 years, the prognostic 
contribution of clinical breast cancer subtype persisted among patients diagnosed with breast 
cancer brain metastases. Interestingly, receipt of systemic therapy following CNS recurrence 
was an important predictor of survival following brain metastases. In contrast to that 
observed in non-Triple-negative subtypes, a recent series indicates the administration of 
chemotherapy following WBRT in the setting of Triple-negative breast cancer brain 
metastases does not improve survival10. Our data continues to highlight the dire need for 
novel systemic approaches capable of improving outcomes for patients diagnosed with 
Triple-negative breast cancer brain metastases across all racial and age groups.
In our series of patients treated at UNC Chapel Hill between 1988 – 2008, survival 
following brain metastases arising from Triple-negative breast cancer was 0.24 years 
compared to 1.19, 0.8 and 1.27 years for HR−/HER2+, HR+/HER2− and HR+/HER2+ 
subtypes, respectively. Our results are consistent with several, albeit few, reports evaluating 
the prognostic implication of subtype among patients with breast cancer brain 
metastases9, 10, 12. Among 222 patients treated at the Cancer Center, Warsaw, Poland from 
2003 – 2006, Niwinski et al. reports median survival following brain metastases in Triple-
negative, HER2-positive, and Luminal (endocrine sensitive) subtypes was 3.7, 9 and 15 
months, respectively.11 A similar series by Nam et al. retrospectively evaluated 126 patients 
with breast cancer brain metastases treated at the National Cancer Center Hospital, Goyang, 
Korea from 2001 – 2006. Survival was shortest from brain metastases to death among 
patients with Triple-negative and Luminal A (HR+/HER2−) breast cancer (3.4 and 4.0 
months) compared to HER2 (HR−/HER2+) and Luminal B (HR+/HER2+) counterparts (9.0 
and 5.0 months; p = 0.0113)12. Our analysis also indicates poor prognosis following a 
diagnosis of brain metastases arising from HR+/HER2− breast tumors – an observation 
likely attributable to the fact that CNS recurrence is a late occurrence in the natural history 
of HR+/HER2− breast cancer.
Recognizing that younger women of AA descent are at higher risk for the development of 
Triple-negative breast cancer and both race and age differences are known to affect breast 
cancer survival,13–15, 17 one of the goals central to our analysis was to examine the 
prognostic influence of race and age following CNS recurrence. Examining race as a single 
prognostic factor, survival following CNS recurrence was not influenced by ethnicity across 
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subtypes. However, AA patients experienced shorter OS and recurred within the CNS more 
rapidly than non-AA patients. Careful review of race-specific treatments indicates a lower 
proportion of AA women received > 3 lines of chemotherapy in the metastatic setting 
compared to non-AA patients. Although this study is not designed to identify causality for 
this observation, receipt of fewer lines of chemotherapy may partially explain both inferior 
OS and earlier recurrence in the CNS among AA patients. Similar to race, age as a single 
prognostic factor did not influence survival following CNS recurrence across subtypes. 
Interestingly, within this cohort of patients all of whom developed brain metastases from 
breast cancer, median age at breast cancer diagnoses was young, 44 years. Moreover, 31% 
of patients were aged < forty at initial diagnosis. Per the US Surveillance, Epidemiology and 
End Results (SEER) database, the median age at breast cancer diagnosis is 61 years (2002 – 
2006) and 7% of women in the US diagnosed with breast cancer in are aged < 40 years17, 18. 
Although determining risk factors for the development of CNS recurrence was not the 
purpose of this study, prior reports indicate young age to be a risk factor for the development 
of breast cancer brain metastases and our data is supportive of this finding2.
Several limitations inherent to this study should be addressed. First, patients included in this 
analysis all developed CNS metastases from breast cancer and were treated at a single-
center, academic institution largely on clinical protocols. As such, practice patterns (ie. 
routine use of neo-adjuvant chemotherapy, strong referral base for neurosurgical resection, 
etc.) may have introduced bias. Moreover, results from this self-contained dataset may not 
be generalizable across the entire breast cancer population, but add to the existing literature 
surrounding the high risk population who recur within the CNS. In addition, the database 
spans a long period (1998 – 2008) during which time newer therapies have been introduced 
into clinical practice. Thus, results may not be entirely applicable to the modern-day breast 
cancer patient population and should be interpreted within the confines of the study period. 
Secondly, an IHC surrogate was employed to assign breast cancer subtype from archival, 
paraffin-embedded tissues. As subtype assignment via gene expression is available only in 
research settings, this approach is generally accepted when fresh, frozen tissues samples are 
unavailable for analysis13. Breast cancer subtype assignment was based primarily on 
receptor status acquired from primary breast tumors. Although discordance between primary 
breast tumor and brain metastases ER, PR and HER2 status may occur19, routine biopsy of 
the CNS is not feasible (or necessary) in all cases. Moreover, receptor concordance between 
the clinical database and repeat IHC on available tissues was < 100%. As such, rare cases of 
subtype misclassification may have occurred. Finally, while the sample size of this 
retrospective analysis is comparable to works within the field, detection of small to 
moderate interactions between race, subtype, and survival may have been limited by the 
evaluation of subsets of the larger patient population.
In summary, this informative study is, to our knowledge, the first to examine the prognostic 
interplay of breast cancer subtype, race and age among patients with brain metastases in a 
racially-diverse US patient population. Results presented herein illustrate clinical breast 
cancer subtype maintains prognostic significance, independently of race and age, among 
patients with breast cancer brain metastases. Moreover, Triple-negative breast cancer, 
regardless of race or age confers the worst prognosis – a finding that is consistent with prior 
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series and continues to highlight the need for the development of novel, targeted agents 
capable of controlling both intracranial and extracranial Triple-negative breast cancer.
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